In anti-cancer therapy, this class of drugs is involved in the cell cycle, apoptosis, and hormonal response, and other aspects of regulation, including intracellular Ca2+ depletion, proteasome degradation to induce cell cycle arrest and transcriptional inhibition of related hormone receptors, and reduction of macrophage activation, while they also induce apoptosis to inhibit cancer cell proliferation by participating in reducing the expression of c-Myc, Bcl2, VEGF, and b-FGF (Wei et al., 2009; Zhang et al., 2013; Fröhlich and Wahl, 2015). The gene discussed is BCL2; the disease is cancer.